 Connection
Larry Moreland to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Larry Moreland has written about Tumor Necrosis Factor-alpha.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.211 |
|
|
|
-
Hwang YG, Moreland LW. Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis. Curr Rheumatol Rep. 2014 May; 16(5):417.
Score: 0.322
-
Patel AM, Moreland LW. Certolizumab pegol: a new biologic targeting rheumatoid arthritis. Expert Rev Clin Immunol. 2010 Nov; 6(6):855-66.
Score: 0.253
-
Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics. 2004; 22(2 Suppl 1):39-53.
Score: 0.157
-
Mikuls TR, Moreland LW. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opin Pharmacother. 2001 Jan; 2(1):75-84.
Score: 0.128
-
Elliott SE, Kongpachith S, Lingampalli N, Adamska JZ, Cannon BJ, Blum LK, Bloom MS, Henkel M, McGeachy MJ, Moreland LW, Robinson WH. B cells in rheumatoid arthritis synovial tissues encode focused antibody repertoires that include antibodies that stimulate macrophage TNF-a production. Clin Immunol. 2020 03; 212:108360.
Score: 0.120
-
Moreland LW. Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun; 66(6):367-74.
Score: 0.114
-
Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol Suppl. 1999 May; 57:7-15.
Score: 0.114
-
Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis. 1999; 48(3):1-4.
Score: 0.111
-
Koopman WJ, Moreland LW. Rheumatoid arthritis: anticytokine therapies on the horizon. Ann Intern Med. 1998 Feb 01; 128(3):231-3.
Score: 0.104
-
Singh D, Henkel M, Sendon B, Feng J, Fabio A, Metes D, Moreland LW, McGeachy MJ. Analysis of CXCR5+Th17 cells in relation to disease activity and TNF inhibitor therapy in Rheumatoid Arthritis. Sci Rep. 2016 12 22; 6:39474.
Score: 0.097
-
Sieberts SK, Zhu F, Garc?a-Garc?a J, Stahl E, Pratap A, Pandey G, Pappas D, Aguilar D, Anton B, Bonet J, Eksi R, Forn?s O, Guney E, Li H, Mar?n MA, Panwar B, Planas-Iglesias J, Poglayen D, Cui J, Falcao AO, Suver C, Hoff B, Balagurusamy VSK, Dillenberger D, Neto EC, Norman T, Aittokallio T, Ammad-Ud-Din M, Azencott CA, Bell?n V, Boeva V, Bunte K, Chheda H, Cheng L, Corander J, Dumontier M, Goldenberg A, Gopalacharyulu P, Hajiloo M, Hidru D, Jaiswal A, Kaski S, Khalfaoui B, Khan SA, Kramer ER, Marttinen P, Mezlini AM, Molparia B, Pirinen M, Saarela J, Samwald M, Stoven V, Tang H, Tang J, Torkamani A, Vert JP, Wang B, Wang T, Wennerberg K, Wineinger NE, Xiao G, Xie Y, Yeung R, Zhan X, Zhao C, Greenberg J, Kremer J, Michaud K, Barton A, Coenen M, Mariette X, Miceli C, Shadick N, Weinblatt M, de Vries N, Tak PP, Gerlag D, Huizinga TWJ, Kurreeman F, Allaart CF, Louis Bridges S, Criswell L, Moreland L, Klareskog L, Saevarsdottir S, Padyukov L, Gregersen PK, Friend S, Plenge R, Stolovitzky G, Oliva B, Guan Y, Mangravite LM. Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. Nat Commun. 2016 08 23; 7:12460.
Score: 0.094
-
Wampler Muskardin T, Vashisht P, Dorschner JM, Jensen MA, Chrabot BS, Kern M, Curtis JR, Danila MI, Cofield SS, Shadick N, Nigrovic PA, St Clair EW, Bingham CO, Furie R, Robinson W, Genovese M, Striebich CC, O'Dell JR, Thiele GM, Moreland LW, Levesque M, Bridges SL, Gregersen PK, Niewold TB. Increased pretreatment serum IFN-?/a ratio predicts non-response to tumour necrosis factor a inhibition in rheumatoid arthritis. Ann Rheum Dis. 2016 10; 75(10):1757-62.
Score: 0.089
-
Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J, Hughes LB, de Vries N, Raychaudhuri S, Alfredsson L, Askling J, Wedr?n S, Ding B, Guiducci C, Wolbink GJ, Crusius JB, van der Horst-Bruinsma IE, Herenius M, Weinblatt ME, Shadick NA, Worthington J, Batliwalla F, Kern M, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Seldin MF, Moreland LW, Behrens TW, Allaart CF, Criswell LA, Huizinga TW, Tak PP, Bridges SL, Toes RE, Barton A, Klareskog L, Gregersen PK, Karlson EW, Plenge RM. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2010 Jul; 62(7):1849-61.
Score: 0.062
-
Bradford RD, Pettit AC, Wright PW, Mulligan MJ, Moreland LW, McLain DA, Gnann JW, Bloch KC. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis. 2009 Sep 15; 49(6):924-7.
Score: 0.058
-
Turkiewicz AM, Moreland LW. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum. 2007 Apr; 56(4):1051-66.
Score: 0.049
-
Shatin D, Rawson NS, Curtis JR, Braun MM, Martin CK, Moreland LW, Becker AF, Patkar NM, Allison JJ, Saag KG. Documented tuberculin skin testing among infliximab users following a multi-modal risk communication interventions. Pharmacoepidemiol Drug Saf. 2006 Jan; 15(1):11-8.
Score: 0.045
-
Moreland L. Unmet needs in rheumatoid arthritis. Arthritis Res Ther. 2005; 7 Suppl 3:S2-8.
Score: 0.043
-
Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep; 50(9):2750-6.
Score: 0.041
-
Baker JF, ODell JR, England BR, Giles JT, Newcomb JA, George MD, Thiele G, Moreland L, Bridges SL, Curtis JR, Mikuls TR. Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis. Ann Rheum Dis. 2024 Mar 12; 83(4):429-436.
Score: 0.040
-
Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003 Jun; 25(6):1700-21.
Score: 0.038
-
Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003 Jan; 48(1):35-45.
Score: 0.037
-
Misischia RJ, Moreland LW. Rheumatoid arthritis: developing pharmacological therapies. Expert Opin Investig Drugs. 2002 Jul; 11(7):927-35.
Score: 0.035
-
Furst DE, Breedveld FC, Burmester GR, Crofford L, Emery P, Feldman M, Kalden JR, Kavanaugh A, Keystone E, Lipsky PE, Maini RN, Moreland L, Smolen JS, Van De Putte L, Vischer T, Weinblatt M, Weissman M. Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis. 1999 Nov; 58 Suppl 1:I129-30.
Score: 0.029
-
Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedr?n S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP, Crusius JB, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PL, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges SL, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013 Mar; 9(3):e1003394.
Score: 0.019
-
Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL. Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec; 5(8):641-7.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|